News | May 28, 2021
Remdesivir demand was exaggerated: Dr. Sharvil Patel
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
